Lempo Therapeutics ^{For Profit}

Lempo Therapeutics is a company that uses CRISPR-based treatment for removing the Myeloperoxidase (MPO) gene in CD34+ stem cells to eliminate the autoantigen in several autoimmune diseases and dramatically reduces the damages caused by excessive activation of the immune system in other diseases. Their core product MP-001 is in the pre-clinical stage with two lead rare, life-threatening indications: MPO-ANCA associated Glomerulonephritis (AAGN) and Pulmonary Arterial Hypertension (PAH). The company plans to expand their pipeline to many indications without requiring any changes to the product itself and while relying on the same regulatory framework and manufacturing operation. The company was established in 2017 by Oren Glanz, CEO, who was diagnosed with Multiple Sclerosis (MS) and confined to a wheelchair because of it. The company's contact information is O: +972-54-4746740, info@lempo-tx.com, Innovation Hub, 86 Sheshet Hayamim, st., Binyamina, Israel, 3050000.